Biohaven is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological diseases, including rare disorders. Biohaven’s product candidates are small molecules based on two distinct mechanistic platforms—calcitonin gene-related peptide (CGRP) receptor antagonists and glutamate modulators—which the company believes have the potential to significantly alter existing treatment approaches across a diverse set of neurological indications with high unmet need in both large markets and orphan indications.
The most advanced product candidate from its CGRP receptor antagonist platform is rimegepant, which Biohaven is developing for the acute treatment of migraine. The most advanced product candidate from its glutamate modulation platform is troriluzole (formerly trigriluzole and BHV-4157), which is being developed for the treatment of ataxias with an initial focus on spinocerebellar ataxia (SCA). The company’s second most advanced product candidate from its glutamate modulation platform is BHV-0223, which is being developed for the treatment of amyotrophic lateral sclerosis (ALS), a neurodegenerative disease that affects nerve cells in the brain and spinal cord. Biohaven has received orphan drug designation from the FDA for BHV-0223 in ALS.